5 December 2007
Qualyst and SOLVO Biotechnology announce alliance for B-CLEAR® in Europe
Raleigh, NC. U.S.A. and Budapest, Hungary
SOLVO Biotechnology, a leading provider of drug transport technologies, cell products and contract in vitro and in vivo laboratory services, and Qualyst, Inc., a leader in the development and commercialization of novel and proprietary absorption, distribution, metabolism, excretion and toxicity (ADMET) technologies, today announced that SOLVO has obtained a license to Qualyst's B-CLEAR® system. B-CLEAR® products and services are projected to be available in Europe from SOLVO in early 2008. Financial details were not disclosed.
B-CLEAR® is a patented system for the in vitro assessment and in vivo prediction of hepatobiliary disposition, hepatic uptake, hepatic efflux, biliary clearance and drug transport. B-CLEAR® offers research organizations the ability to generate physiologically-relevant data and enable decision making in critical areas related to hepatic transport and adverse drug interactions, helping to avoid costly drug development challenges. B-CLEAR® can be used as an early discovery screen for promotion of compounds, as a source of lead optimization guidance, and as a tool to address development-stage drug transport and drug-drug interaction challenges.
About Qualyst, Inc.
Qualyst commercializes novel and proprietary ADMET products for drug discovery and development. Qualyst's products allow pharmaceutical and biotechnology researchers to make faster, better decisions regarding drug candidate compounds, saving valuable time and research dollars in the process.
For additional information, please refer to the company's web site at www.qualyst.com or call 919-313-6500.
About SOLVO,
SOLVO Biotechnology - "The Transporter Company" is a privately held biopharmaceutical company established in 1999 by a group of pre-eminent scientists working in the areas of ABC transporter proteins and multi-drug resistance at leading Hungarian universities. SOLVO has been the pioneer and the leader in the commercialization of Membrane Transporter technologies, including therapeutics, diagnostics and drug discovery assays.
For additional information, please refer to the company's web site at www.solvo.com or email 
.
 |  |
| QUALYST CONTACT: Marc Sedam Chief Business Officer info@qualyst.com 919-313-6511 |
SOLVO CONTACT: Gábor Heltovics Business Development Director info@solvo.com +36-23-503940 |
|
For Customers in Japan:
Funakoshi (distributor of SOLVO membrane products)
Iwaki (exclusive distributor of SOLVO Fee-for Service Screenings, distributor of SOLVO membrane products)
|
| Privileged/confidential information may be contained in this message. This communication is confidential and intended solely for the addressee(s). Unauthorized distribution, modification or disclosure of the contents may be unlawful. If you receive this in error, please notify the sender and delete it from your system. If you are not the addressee indicated in this message (or responsible for delivery of the message to such person), you may not copy or deliver this message to anyone. |
If you wish to
unsubscribe, please send a letter to 
with 'unsubscribe' in the subject field. |